{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-22-000048","form_type":"8-K","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.688393+00:00","generated_at":"2026-06-22T08:00:09.716418+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pulmonx Q3 revenue $13.5M, cuts FY guidance to $51.5-52.5M; extends credit line to 2027","bullets":["Q3 revenue $13.5M (+2% YoY, +7% constant currency); US $8.4M (+22%), intl $5.1M (-20%).","Net loss $14.2M ($0.38/sh) vs $10.2M ($0.28) in Q3 2021; gross margin 75% vs 73%.","FY2022 revenue guidance cut to $51.5-52.5M from $55-60M; opex guidance lowered to $98-100M.","Extended loan with CIBC: maturity to Oct 2027, new $20M tranche, 24-month interest-only period.","Japan MHLW agreed to approve Zephyr Valves; AeriSeal data may expand treatable patient pool."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-22-000048","json":"https://secwatch.observer/filing/0001127537-22-000048.json","markdown":"https://secwatch.observer/filing/0001127537-22-000048.md","text":"https://secwatch.observer/filing/0001127537-22-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/0001127537-22-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/lung-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:00:09.716418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"574ac55bc914d0801d2db940bfc0d7a4eb49bdc9","claim":"Pulmonx Corp reported third quarter ended September 30, 2022 results: revenue 13.5 million.","evidence_excerpt":"invasive treatments for lung disease, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights • Achieved worldwide revenue of $13.5 million in the third quarter of 2022, a 2% increase over the same period last year and an increase of 7% on a constant currency basis, driven by U.S. revenue of $8.4 million representing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/0001127537-22-000048-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"13.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9c3efd9c2d7e3e0c19de588415ab8be43185a968","claim":"Pulmonx Corp reported full year 2022 results: revenue 51.5 million to 52.5 million. Guidance lowered.","evidence_excerpt":"Pulmonx is updating its full year 2022 revenue guidance to be in the range of $51.5 million to $52.5 million, as compared to previously communicated guidance of $55 million to $60 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/0001127537-22-000048-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"51.5 million to 52.5 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"7947ba2ce85d7d4f8b58e7d11803f211baa6f7e0","claim":"Pulmonx Corp amended Third Amendment to Amended and Restated Loan and Security Agreement with Canadian Imperial Bank of Commerce valued at $20,000,000 (effective 2022-10-31).","evidence_excerpt":"On October 31, 2022, the Company executed a Third Amendment to Amended and Restated Loan and Security Agreement (the “Third Amendment”) with Canadian Imperial Bank of Commerce (“CIBC”), which amended certain provisions of the Company’s existing Amended and Restated Loan and Security Agreement, dated as of March 29, 2021","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1127537/000112753722000048/0001127537-22-000048-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Canadian Imperial Bank of Commerce"},{"label":"Value","value":"$20,000,000"},{"label":"Effective","value":"2022-10-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}